Scott R. Solomon, MD, medical director of the Blood and Marrow Transplant Matched Unrelated Donor Program and the Stem Cell Processing Laboratory, and a physician in the Leukemia Program, at Northside Hospital, discusses the rationale for examining lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphoma (LBCL).

It is well known that CD19-targeted CAR T-cell therapies have demonstrated significant efficacy in patients with relapsed/refractory LBCL. As such, this modality has become the standard of care in the third-line setting, according to Solomon. One important question that still needs to be addressed is whether liso-cel will continue to maintain efficacy in patients who have had prior exposure to anti-CD19 therapies, including monoclonal antibodies, bispecific antibodies, or antibody-drug conjugates, Solomon says.

CD19-targeted regimens are now commonly used in clinical research that is being done in patients with LBCL, and many patients who have been exposed to anti-CD19 agents are going on to receive CAR T-cell therapy, Solomon concludes.

Videos

Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCL

Scott R. Solomon, MD, medical director, Northside Hospital Blood and Marrow Transplant Matched Unrelated Donor Program and Northside Hospital Stem Cell Processing Laboratory, physician, Northside Hospital Leukemia Program, discusses the effects of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma (B-NHL) who were previously treated with CD19-directed therapies. 

During the 2021 Transplantation and Cellular Therapy Meetings, findings from a post-hoc analysis of the phase 1 TRANSCEND NHL 001 trial were presented virtually. The results showed that 11 out of 12 patients with relapsed/refractory B-NHL who had previously received anti-CD19 therapy responded to liso-cel treatment, Solomon says. Moreover, 2 patients had complete responses, 3 had partial responses, and 1 had stable disease. 

Five patients experienced a duration of response to liso-cel of 9 months or longer, and 4 patients had ongoing responses at the time of the data cut-off, Solomon says. As such, these data suggest that prior exposure to CD19-directed therapy does not negatively affect the efficacy of liso-cel in this patient population, concludes Solomon.

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.  



Scott R. Solomon, MD

Articles

Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCL

Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL